Nike upgraded, Sportradar initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.

Top 5 Upgrades:

• Argus upgraded Nike (NKE) to Buy from Hold with an $85 price target. The recovery in Nike’s stock is underway as the company is utilizing the e-commerce channel to improve pricing, the firm tells investors in a research note.
• Raymond James upgraded Hyatt (H) to Strong Buy from Market Perform with a $165 price target following the announcement that the company had reached an agreement to sell the entirety of its Playa owned real estate.
• Goldman Sachs upgraded Hasbro (HAS) to Buy from Neutral with a price target of $85, up from $66. The company is well-positioned to exceed consensus expectations in 2026 and beyond across revenue, adjusted EBITDA, and free cash flow driven by robust demand for Magic: The Gathering’s new Universes Beyond sets, execution against the company’s new self-published digital gaming strategy, and better-than-feared performance from the toy business as tariff relief, market share growth, and pricing levers insulate segment profitability, the firm tells investors in a research note.
• Barclays upgraded Ionis Pharmaceuticals (IONS) to Overweight from Equal Weight with a price target of $57, up from $51, ahead of Tryngolza Phase 3 CORE/CORE2 data in severe hypertriglyceridemia due likely in September.
• Wells Fargo upgraded Cintas (CTAS) to Equal Weight from Underweight with a price target of $221, up from $196. The firm says the company has weathered the tough macro better than peers, and Wells now sees an attractive opportunity for Cintas to further its share gains.

Top 5 Downgrades:

• Goldman Sachs downgraded Textron (TXT) to Neutral from Buy with a price target of $85, down from $95. While the firm still believes that business jet supply and demand is tight and that the FLRAA win is a large new earnings contributor, upside in the stock has yet to materialize.
• TD Cowen downgraded Sweetgreen (SG) to Hold from Buy with a price target of $15, down from $25. The firm says its concern on same-store sales misses began in Q2, though it extends to the optimistic second half of 2025 acceleration embedded in consensus, while there is risk of not returning to normalized same store sales in 2026.
• KeyBanc downgraded Lineage (LINE) to Sector Weight from Overweight without a price target. Given a challenging operating environment stemming from softer demand and elevated levels of new supply, the Cold Storage REITs remain out of favor and the outlook for conditions to stabilize remains uncertain, the firm tells investors in a research note.
• Goldman Sachs downgraded Coterra Energy (CTRA) to Neutral from Buy with an unchanged $31 price target. In recent months, Coterra has more closely traded to oil producer peers and as a result has underperformed gas-focused E&P peers given the relatively more positive gas versus oil outlook, the firm added.
• UBS downgraded Southern Copper (SCCO) to Neutral from Buy with a $105 price target. UBS feels the downside risk to copper prices over the next six months – due to macro uncertainty and trade war issues – limits upside risk, and believes the stock is currently “risk-reward balanced.”

Top 5 Initiations:

• Truist initiated coverage of Sportradar (SRAD) with a Buy rating and $33 price target. Sportradar, as the largest B2B partner for the sports betting industry, has become “increasingly important” to customers that include operators, leagues and media, says the firm, which sees upside to 2027 financial targets through higher market growth and new state legalization, in-play mix, and development of new revenue drivers.
• Truist initiated coverage of Genius Sports (GENI) with a Buy rating and $14 price target. The firm views Genius as an “integral B2B partner” for the online sports betting industry sees “a credible path” for the company to approach about $300M in EBITDA by 2028 with increasing in-play betting, new state legalizations and OSB growth.
• Roth Capital initiated coverage of MasTec (MTZ) with a Buy rating and $210 price target. The engineering, procurement, and construction company provides infrastructure solutions for electric/gas utilities, renewable energy, communications, and pipeline industries, notes the firm, which believes MasTec is “one of the best-positioned companies to support the acceleration of the electrical infrastructure buildout.”
• Goldman Sachs initiated coverage of Omada Health (OMDA) with a Buy rating and $29 price target. Considering the growth trajectory, near-term path to profitability, and below peer valuation, the firm sees shares offering a “compelling risk/reward” at current levels. Morgan Stanley, Barclays, JPMorgan, Needham, Canaccord also started coverage of the stock with Buy-equivalent ratings.
• Piper Sandler initiated coverage of Rollins (ROL) with an Overweight rating and $70 price target. Rollins, which has a long track record of “healthy and sustainable growth,” is in the early stages of transitioning from a family-run business to a more modernized public company, which should accelerate growth and “make shares more appealing,” the firm tells investors.